Intrinsiqq
TC BioPharm (Holdings) plc American Depositary Receipt logo

TC BioPharm (Holdings) plc American Depositary Receipt Financials

TCBPY

Compare

All currency values in £ millions unless otherwise noted

Income Statement
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue£0£0£4£2
Operating Income-£13-£14-£12-£7
Non-Operating
Net Interest Expense£0-£0-£7-£3
Income Tax Expense-£1-£1-£2-£1
Net Income
Net Income-£12-£6-£1-£14
Per Share Data
Revenue Per Share£0.00£0.00£17,888.06–
EPS (Basic)-£6,320.89-£3,072.00-£6,112.00–
EPS (Diluted)-£6,320.89-£3,072.00-£6,112.00–
Shares Outstanding1,922.8361,922.836214.922–

TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) financials: revenue, profit and margins

TC BioPharm (Holdings) plc American Depositary Receipt (TCBPY) generated about £0.00 in revenue and -£12 million in net income over the trailing twelve months, growing at roughly 94.3% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is TC BioPharm (Holdings) plc American Depositary Receipt's (TCBPY) revenue?+

TC BioPharm (Holdings) plc American Depositary Receipt generated about £0.00 in revenue over the trailing twelve months. Revenue has grown at roughly 94.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is TC BioPharm (Holdings) plc American Depositary Receipt profitable?+

TC BioPharm (Holdings) plc American Depositary Receipt reported about -£12 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is TC BioPharm (Holdings) plc American Depositary Receipt growing?+

TC BioPharm (Holdings) plc American Depositary Receipt's revenue has compounded at roughly 94.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside TCBPY's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with TCBPY

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing TCBPY

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.